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Background: The counterfeiting of anti-malarials represents a form of attack on global public health in which fake
and substandard anti-malarials serve as de facto weapons of mass destruction, particularly in resource-constrained
endemic settings, where malaria causes nearly 660,000 preventable deaths and threatens millions of lives annually.
It has been estimated that fake anti-malarials contribute to nearly 450,000 preventable deaths every year. This crime
against humanity is often underestimated or ignored. This study attempts to describe and characterize the direct
and indirect effects of counterfeit anti-malarials on public health, clinical care and socio-economic conditions.
Methods: A search was performed using key databases, WHO documents, and English language search engines.
Of 262 potential articles that were identified using a fixed set of criteria, a convenience sample of 105 appropriate
articles was selected for this review.
Results: Artemisinin-based combination therapy (ACT) is an important tool in the fight against malaria, but a sizable
number of patients are unable to afford to this first-line treatment. Consequently, patients tend to procure cheaper
anti-malarials, which may be fake or substandard. Forensic palynology reveals that counterfeits originate in Asia.
Fragile drug regulations, ineffective law-enforcement agencies and corruption further burden ailing healthcare
facilities. Substandard/fake anti-malarials can cause (a) economic sabotage; (b) therapeutic failure; (c) increased
risk of the emergence and spread of resistant strains of Plasmodium falciparum and Plasmodium vivax; (d) an
undermining of trust/confidence in healthcare stakeholders/systems; and, (e) serious side effects or death.
Conclusion: Combating counterfeit anti-malarials is a complex task due to limited resources and poor techniques
for the detection and identification of fake anti-malarials. This situation calls for sustainable, global, scientific
research and policy change. Further, responsible stakeholders in combination with the synthesis and supply of
next generation malaria control tools, such as low-cost anti-malarials, must promote the development of a
counterfeit-free and malaria-free future.
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Counterfeit drugs: a silent tsunami
Counterfeiting is one of the oldest and most profitable
occupations [1]. However, even today, it remains difficult
to detect, investigate or quantify. The World Health
Organization (WHO) estimated that nearly half of the
global pharmaceutical market is occupied by counterfeitCorrespondence: karunamoorthi@gmail.com
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unless otherwise stated.drugs [2]. Recent estimates suggest that nearly 800 fake
drug types [3] are within the legitimate pharmaceutical
market structure, and globally there is a massive increase
in counterfeit or falsified drug sales to over US$75 bil-
lion in 2010, an increase of more than 92% from 2005
[4]. Poverty, weak economies, poor regulatory systems,
short supply, and the rising cost of therapeutic agents
have created a corresponding increase in production of
fake drugs because of the huge profit margin [5].
Both substandard and counterfeit drugs are serious
problems, and remain as one of the most neglected publicral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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more than 60% in Third World countries [7]. WHO esti-
mates about 60% of purchased counterfeited products did
not have any active pharmaceutical ingredient (API), 17%
contain too much or too little API, whilst another 16%
contain the wrong ingredients altogether [8].
Types of counterfeiting
The rising threat posed by counterfeited or falsified
medicines (see definitions on Table 1) is aggravated by
two factors: (i) the most common types of fake drugs,
called ‘lifestyle drugs’ are those used to treat erectile dys-
function or baldness; and, (ii) ‘lifesaving drugs’, meant to
prevent or treat asthma, malaria, cancer, HIV/AIDS, tu-
berculosis, blood pressure and heart conditions, diabetes,
and severe diarrhoea [9]. From 2007 to 2009, online coun-
terfeit medicine trade rose from US$4 to 11 billion via
over 2,930 fraudulent websites [10].
In general, the industrialized economies suffer with
life-style related diseases, whereas in the emerging econ-
omies infectious diseases are a matter of grave concern.
As a result, both the life saving and lifestyle drugs are
much prone to counterfeiting. Besides, people have a
tendency to buy cheaper alternatives paving a way for a
big market of fake drugs.
Nevertheless, the magnitude of this problem is not well-
known or remains scanty. So far, no study has been
conducted to determine and quantify the exact extent of
counterfeiting [11]. Figure 1 shows the clear trend of
pharmaceutical crime incidents in 2012. Although the
crime incident is extremely low in Africa as per the report
of pharmaceutical security institute [11], it is the major vic-
tim of counterfeit drugs, particularly fake anti-malarials,







Gray pharmaceuticalmechanisms and weak law-enforcement agencies. These
agencies are often understaffed and underfunded too.
Fake drugs have flourished due to the emergence and re-
surgence of many infectious diseases, particularly the three
major killer diseases: HIV/AIDs, malaria and tuberculosis.
It is important to note that these diseases are more com-
mon, widespread and destructive in resource-poor settings
of Africa and Asia. Although the traffic of counterfeit anti-
malarials poses a grave threat to all sections of society, it
imposes severe negative socio-economic, clinical and public
health concerns, particularly in the endemic settings of
sub-Saharan Africa and Southeast Asia. Over decades, the
silent ‘tsunami’ of substandard and fake anti-malarials is
poorly understood, undervalued or ignored, which has re-
sulted in hundreds of thousands of preventable deaths and
considerable morbidity every year. Tragically, it is often
tacit, unreported or under-reported in several low- and
middle-income countries (LMICs).
There is a vast literature on the impact of counterfeit
drugs. However, to the best of the author’s knowledge and
understanding, only a limited number of studies report on
the negative impact of counterfeit anti-malarials. In this
perspective, the present scrutiny becomes more significant
and pertinent and is an attempt to determine the global im-
pact of counterfeit anti-malarials in terms of clinical, public
health and socio-economic concerns. It also identifies the
potential associated-risk factors and delineates emerging
opportunities. It could provide some baseline information
for policy-makers, public healthcare experts, and other
stakeholders to design and implement appropriate strat-
egies to confront this modern-age inhuman act. It may em-
power not only a counterfeit-free anti-malarial world, but
also establish the ambitious goal of a malaria-free world
through sustainable, global, scientific research and policies.A pharmaceutical product designed for or used in saving lives.
A pharmaceutical product characterized as improving the quality
of life rather than alleviating or curing disease.
Medicines that are deliberately and fraudulently mislabeled with
respect to identity and/or source.
▪ Deliberately and fraudulently produced and/or mislabeled with
respect to identity and/or source to make it appear to be a
genuine product.
▪ It contains less or more than the required amount of active
pharmaceutical ingredients (API) used in the authentic version or
even contains the correct amount of API but have been
manufactured in unsanitary and unsafe conditions [11].
Genuine drug products which do not meet quality specifications
set for them. If substandard drugs are knowingly produced to
make an unlawful product, they too are considered counterfeit.
It usually has no active ingredient or dangerous substances and
can cause serious harm to patients.
Space is emerging where illicit profiteers are ostensibly marketing
competitive brands without regulatory approval.
Figure 1 Pharmaceutical crime incidents by region, 2012 (Source: Pharmaceutical Security Institute, 2013) [11].
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Identification of studies
The search strategy and terms were developed collabora-
tively with an information specialist. An appropriate search
was conducted in PubMed, Google Scholar, Web of Sci-
ence, EMBASE, Scopus, WHO’s WHOLIS, US Pharmaco-
peia databases, anti-counterfeiting networks, and search
engines in English, using the terms: ‘Anti-malarials/analysis’
or ‘Anti-malarials/standards analysis and packaging of anti-
malarial drugs in Southeast Asia and sub-Saharan Africa’,
‘counterfeit drugs’, ‘substandard drugs’, ‘falsified drugs’, ‘arte-
misinins’, ‘artesunate’, ‘drug resistance’, ‘sub-standard anti-
malarial’ and ‘counterfeit anti-malarial’ to include articles
published without time limitations, i.e., from earliest to
most recent (August 2013). Potentially relevant papers (in
all languages) were accessed in order to review the full text.
The references cited by each relevant paper, review and
book chapter were scrutinized to locate additional potential
papers. In addition, the reference lists of all articles for
which the full text was reviewed were hand-searched, and
the full text of those references that appeared relevant to
counterfeit drugs and counterfeit anti-malarials were
retrieved.
Inclusion criteria
Studies that reported primary data on the prevalence
and potential public health, and clinical and socio-
economic concerns of counterfeit anti-malarials, were
selected by using the Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) guideline
procedure. The titles and abstracts of the identified arti-
cles are checked against predetermined criteria for eligi-
bility (the studies that deal with the various aspects of
counterfeit anti-malarials) and relevant to the study
objectives. Where multiple publications presented iden-
tical data, the most ‘informative version’ of the study
was included. Studies published in a language other thanEnglish were translated, and relevant papers were in-
cluded. The full text of all thus selected studies was ob-
tained, and assessed. Of 262 potential articles identified by
these criteria, 117 studies were included for qualitative
(dealing with phenomena that are difficult or impossible
to quantify mathematically) synthesis and 105 of them
were used for the quantitative synthesis (dealing with
phenomena that are possible to quantify mathematically)
by using the convenience sample method (A statistical
method of drawing representative data by selecting appro-
priate studies because of their ease of access) for obtaining
relevant data presented in this systematic review (Figure 2).
Articles were retrieved from the important databases and
search engines, and were further refined with biblio-
graphic search of these articles.
Exclusion criteria
In the beginning, a total of 262 (228 + 34) articles were
identified through searching various databases (228) and
other sources (34). However, 90 articles were rejected
because of repetition and the resultant 172 articles were
chosen. In the screening phase, 13 studies were excluded
as they reported on lifestyle-related drugs, such as dia-
betes, erectile dysfunction and baldness. Subsequently in
the eligibility phase, 42 articles were eliminated as they
describe anti-infective counterfeit drugs, except malaria
(Figure 2). Nevertheless, it is significant to emphasize
that these excluded studies provided an in-depth know-
ledge for the investigator on the overall prevalence of
counterfeit medicines and their negative impact both in
emerging economies and developed countries.
Risk of bias assessment
Two reviewers independently assessed and screened the
search results by title and abstract for potential eligibil-
ity. Subsequently, the full texts of potentially suitable ar-
ticles were obtained and were further screened for
Figure 2 PRISMA flow diagram showing the exclusion and inclusion of studies for analysis.
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texts were resolved by a third reviewer with expertise in
fake anti-malarials and this was required for three of the
159 screened papers. Consequently the included studies
were further independently assessed for risk of bias. For
observational study designs, risk of bias was evaluated
using a simple pro forma for three domains, namelyselection bias, information bias (differential misclassifica-
tion and non-differential misclassification), and confound-
ing. Risk of bias for each domain was assessed as either
low, unclear or high. Studies that had a low risk of bias in
each domain, including a low risk of confounding, were
classified as having a low overall risk of bias. Qualitative
studies were evaluated for quality using an adapted
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methods systematic reviews incorporating both quantita-
tive and qualitative studies [12,13].Data synthesis and analysis
A data extraction form was developed in Microsoft Excel.
The key details of the included studies are presented in
the Table, sorted by country, year of publication, major
study findings and by first author (see Additional file 1).
In addition to the details in the present review, pharma-
ceutical crime incidents by region, 2012 [11], reports of
poor-quality artesunate (ART) in Africa [6] and reports
of counterfeit anti-malarials in Southeast Asia [14], are
supplemented in terms of graphical presentations.
Meta-analysis was not performed as included studies
were heterogeneous in important aspects, including
populations (different ages and settings), study designs
(cross-sectional, case-control, cohort) and variable defi-
nitions (including different definitions of counterfeit
drugs, particularly anti-malarial and outcomes).Results
The study selection process is shown in Figure 3 as a
PRISMA flow diagram. Of 262 potentially relevant,
unique citations from all literature searches, 105 studies
met the inclusion criteria. Sixty-two studies were empir-
ical research studies, three were book chapters, two were
from conference, and 14 involved meta-analyses, with
the remaining 18 involving case reports or press releases.
Nearly half of the studies were carried out in the WHO-
defined African region (n = 50), fifteen in the Southeast
Asian region, nine were out of WHO-conducted studies
and reports, and the remaining thirty studies from the
rest of the world; the majority of them were published
after 1990. About nine out of ten studies described the
prevalence, existing challenges, emerging opportunities
and public health impact of fake or substandard anti-
malarials in malaria-endemic settings of Africa and
Southeast Asia. The remaining studies examined theFigure 3 Counterfeit Detection Device (CD-3) (Credit: US-FDA,
2013) [60].actual extent of counterfeit drugs as an issue of clinical,
public health and socio-economic concern worldwide.
Discussion
Impact of counterfeit drugs: quite avoidable
Counterfeiting undermines public trust, credibility with
healthcare systems/providers, and potentially leads to
non-adherence of patients to their life-saving drugs or im-
portation of expensive, branded medicines [15]. The qual-
ity of commercially available drugs varies greatly among
countries, due to the lack of strict regulations and to
deficient quality control practices. In some countries,
even the amount of active ingredient may be incorrect.
In addition, poor formulation techniques can greatly
affect the quality of medicine by slow-release of active
ingredients. Sometimes drugs may be contaminated
with other substances and by poor storage conditions,
when humid, tropical environments may contribute to
chemical degradation of several pharmaceuticals [16].
Emerging economies: an opportunity of counterfeiters
Less-developed countries are often a target for counter-
feiters, since the cost of legitimate drugs may be unafford-
able for a large proportion of a sizable population, and
consequently patients prefer to use cheaper versions than
expensive, genuine ones. In addition, regulatory and law
enforcement systems remain weak. Counterfeiting of life-
style drugs such as Viagra or cancer medicines is more
widespread in developed countries [17]. Counterfeiters are
opportunistic criminals motivated by profits yet with lim-
ited legal penalties [18], and they produce fake drugs out
of starch, chalk and a variety of toxic active ingredients
[19,20], for diseases, such as malaria, that severely affect
the underprivileged section of society [7].
A study found that the majority of the fake anti-
malarials originated from east Asia [6] and distributed
through different channels, such as government and pri-
vate hospitals, pharmacies or other legitimate or illegit-
imate distributors in the emerging economies [21].
Many counterfeit medications remain undetected within
the legitimate supply chain [18]. It has been estimated
that fake drugs for malaria and tuberculosis potentially
kill over 700,000 people every year [22]. One third of
anti-malarial drugs in disease-endemic regions of sub-
Saharan Africa are fake [23]. This is an issue that needs
to be dealt with via regional, national and international
policies [24] with workable cooperation.
Global burden of malaria
Malaria continues to be a massive global public health
problem and it is prevalent in 104 countries. It has been es-
timated that nearly half of the world population (3.4 billion
people) is at risk [25,26]. Although it is a preventable and
curable illness, it remains one of the most important causes
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Saharan Africa [27]. WHO estimates that there were about
219 million cases of malaria in 2012 (with an uncertainty
range of 154 million to 289 million) with more than 627
000 deaths (Table 2). Most deaths have occurred among
children under five years of age living in Africa, where a
child dies from malaria for every single minute. Tragically,
in Africa, where 80% of malaria cases are treated at home,
the disease infact kills one child in 20 before the age of five
[26].
Existing malaria control interventions: good companions
Malaria is a disease of poverty and a cause of poverty [28].
It is quite understandable that countries with higher pro-
portions of their population living in poverty (less than US
$1.25 per person per day) have higher mortality rates
from malaria [26]. It imposes a severe negative public
health and socio-economic impact on Third WorldTable 2 Malaria an overview (WHO, 2013) [26]
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3.4 billion Nearly half of
Clinical cases (2012)
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12 billion US$ Per year in dir
Costs of interventions
1.39 US$ Long-lasting in
0.90 - 1.40 US$ Course of arte
0.30 - 0.40 US$ Course of arte
0.50 US$ Rapid diagnoscountries, where malaria is likely to be endemic (hypo-,
meso-, hyper-, or holo-endemic) in nature [28]. At the
moment, in many malaria-endemic countries, malaria
control is one of the formidable challenges due to: (a)
widespread resistance against conventional chemical in-
secticides, particularly the emergence of ‘behavioural re-
sistance’ to pyrethroid ITNs in 64 countries [29]; (b) lack
of sufficient access to reliable diagnostic tools and rational
treatment with ACT [30]; (c) widespread poverty and eco-
system degradation [28]; (d) fragile healthcare systems
[28]; (e) emergence and spread of multidrug-resistant
strains of P. falciparum; and, (f) lack of reliable vaccine
[30-32].
Despite these challenges, this decade is considered to be
significant in malaria history. This is because over the past
ten years there has been an impressive increase in inter-
national funding and substantial commitment by govern-
ments of endemic countries, donors and global malariathe world population.
laria cases occur in Africa.
rom Africa
laria deaths occur in 18 most affected countries
mong children under 5 years of age
occurs in Nigeria and Democratic Republic of Congo
tries
aria transmission
7% of malaria cases, (an estimated 103 million)
Republic of the Congo
blic of Tanzania
ect losses, lost; 1.3% of GDP growth per year for Africa.
secticidal net that lasts for three years: per person per year of protection
misinin-based combination therapy (ACT) for an adult
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aria prevention, control and elimination strategies. Conse-
quently, the international community can postulate the
long-term, ambitious goal of malaria elimination [32].
Vector control is considered to be a cornerstone of mal-
aria control: to manage vector populations and eventually
to reduce/interrupt the disease transmission. Existing mal-
aria control interventions offer highly encouraging results
and have afforded a unique opportunity to eliminate mal-
aria in a few countries [32]. The WHO estimates that the
malaria related illness and mortality have been dramatic-
ally declining [26]. There is a ray of hope as the malaria
map shrinks and malaria incidence falls and some coun-
tries may consider attacking the remaining foci with an
elimination agenda by employing front-line vector control
tools such as the distribution of long-lasting, insecticide-
treated mosquito nets, effective case management with
potent anti-malarials, selective intradomicillary spraying
and source reduction [33]. However, the heavy reliance on
pyrethroids has led to the emergence of resistance in a
wide variety of malaria-endemic settings [34]. It is consid-
ered to be a potential threat to the global public health
[35]. The continuous persistence of substandard and fake
anti-malarials further aggravates the synthesis and spread
of resistant strains against affordable drugs such as chloro-
quine, which ultimately led to an amendment of treatment
policy to costlier anti-malarials, such as ACT in malaria-
endemic countries [36].
Artemisinin combination therapy: a hope
Mode of mechanism
The use of combination chemotherapy is the current in-
novative strategy to effectively combat malaria. It involves
the use of a short half-life artemisinin drug in combination
with a long half-life conventional tablet [37]. The artemisi-
nin kills the parasites and is excreted quickly, resulting in
the re-emergence of the parasites after a period of time,
but when it is administered in combination with a longer
half-life anti-malarial, it achieves complete eradication of
the parasites and averts the recrudescence that occurs
with the use of artemisinin monotherapy [38].
WHO recommends ACT as first-line treatment for fal-
ciparum malaria worldwide [39]. In addition, parenteral
artesunate, an artemisinin derivative, became the treat-
ment of choice for severe malaria in adults after it was
shown to reduce mortality by 35% compared with quin-
ine [40]. Artemisinin derivatives are characterized by a
rapid mode of action against gametocytes (the sexual
stages) of the parasite that infects mosquitoes [41,42]. In
2011, 278 million courses of ACT were procured for the
public and private sectors in endemic countries - up
from 182 million in 2010, and just 11 million in 2005
[26], and in Fiscal Year 2012, the President’s Malaria Ini-
tiative procured more than 73 million treatments.A potential target of modern counterfeiters
ACT is one of the potential anti-malarials that has been
well-tolerated. It saves millions of lives every year. The ar-
temisinin compounds are derived from the plant Qinghao
(Artemisia annua; Asteraceae), which takes nearly six
months to grow and produces artemisinin. Its chemical
modification has led to a series of potential anti-malarial
drugs (artemether, ART and arteether) [25]. It is in short
supply and there is massive demand [7]. In addition, ACT
is relatively expensive: the cost of a course for an adult
and a young child is US$ 1.20-3.50 and 0.30-0.40, respect-
ively [43]. There is demand for cheaper versions amongst
the poorest and most vulnerable in society, which is the
major driving force to establish counterfeit anti-malarial
industries to produce and distribute fake anti-malarials in
Third World countries, where widespread corruption, in-
sufficient drug regulation and weak law enforcement are
common [6,44].
Insufficient amenities and ability to detect and identify
the quality of anti-malarials, poor consumer and health-
worker knowledge about these drugs and lack of punitive
action (inflicting a punishment) against counterfeiters
make these drugs attractive targets for counterfeiters
[44,45]. Sophisticated counterfeits have been reported in
Asia [46] resulting in a number of cases of increased mor-
bidity and mortality in recent years [7] which has gener-
ated concern that a similar problem would emerge in
Africa [7,47]. Poorer populations living in rural, remote
areas and international travellers/tourists from non-
endemic areas are paying a high price for the counterfeit
anti-malarials. Fake ART has been reported to be circulat-
ing in Africa at least since 2001 [7].
Counterfeit anti-malarials: a silent epidemic in malaria-
endemic settings
Substandard and counterfeit anti-malarial drugs are a
foremost concern in developing economies, particularly in
the holo/hyper-endemic settings of sub-Saharan Africa
[11] and Southeast Asia. Medicines for Malaria Venture
(MMV) recognizes that counterfeiting of anti-malarials is
a multibillion-dollar business, with well sophisticated op-
erators who evade detection by drug-regulatory author-
ities [48]. WHO estimates that fake anti-malarials cause
up to 20% (200,000 people) of the one million malaria
deaths worldwide each year. A recent International Policy
Network (IPN) study [11] estimates the actual burden
could lead to 450,000 preventable deaths every year.
ART has become the target of an extremely sophisti-
cated and prolific counterfeit drug trade, both in terms of
ART tablets and packaging [7,47,49,50]. The counterfeit/
substandard anti-malarial medicines may contain inappro-
priate concentrations of active ingredients, contamination
with other drugs or toxic impurities, poor quality ingredi-
ents, poor stability and inadequate packaging [51]. The
Karunamoorthi Malaria Journal 2014, 13:209 Page 8 of 13
http://www.malariajournal.com/content/13/1/209endemic countries of sub-Saharan Africa and Southeast
Asia have become more vulnerable to counterfeiting, and
are badly affected by fake anti-malarials. They were often
failed for chemical analysis, packaging analysis, or were
falsified.Epidemiology
Counterfeit anti-malarials in Africa: required stringent
actions
Over the past decade, a dramatic rise in fake anti-malarials
has become one of the top public health issues in sub-
Saharan Africa. The illegal production, distribution and
sale of counterfeit drugs represent more than 50% of the
pharmaceutical market in several African countries [52].
Interpol estimates that 30% of anti-malarials circulating
in Africa are either counterfeit or of inferior quality. A
recent study found that 44% of samples from Senegal
and 30% from Madagascar could be qualified as of infer-
ior quality [53]. Seven collections of artemisinin deriva-
tive monotherapy, ACT and halofantrine anti-malarial
of suspicious quality were collected in 2002/10 in 11
African countries (see Figure 1 in reference [6]) and sub-
standard/counterfeit or degraded ART and ART+ amodia-
quine were found in eight countries. Pollen analysis reveals
that the fake drugs originated from East Asia [6].Table 3 Negative impacts of counterfeit antimalarials
S. No. Negative Socio-cultural-clinical-Public Health Impacts
1. Economic sabotage
2. Therapeutic failure
3. Increase the risk of emergence and spread of resistance strains
4. Undervalue the trust/confidence on healthcare stakeholders
5. Loss of trust on healthcare systems
6. Adverse side-effects
7. Even deathCounterfeit anti-malarials in Southeast Asia: educate the
public
In Asia, counterfeiting of anti-malarials is the major con-
cern in China, Thailand, Indonesia, Vietnam, Cambodia,
and Laos [54]. Surveys indicate that up to 40% of
ART was counterfeit in this region. Lack of any active
ingredient is a typical problem, but there are fakes
with the correct ingredients yet with deficient dose, or in
fake packaging, or containing the wrong ingredients [54].
Newton et al. [14] found that of 104 shop-bought ‘artesu-
nate’ samples from Cambodia, Laos, Myanmar (Burma),
Thailand, and Vietnam, 38% did not contain ART.
In an unprecedented, international collaboration, a study
found that half of the samples [(49.9% (195/391)] contained
no active ingredient or too little to have any benefit. Chem-
ical analysis demonstrated a wide diversity of the wrong
active ingredients, including banned pharmaceuticals and
carcinogens [55]. Dondorp et al. [49] reported that tablet
packs are labelled as ‘artesunate’ but 53% did not contain
any active ingredient. Fake blister packs are often hard to
distinguish from their genuine counterparts. Of the 44
mefloquine samples, 9% contained <10% of the expected
amount of active ingredient. ACT were found to be coun-
terfeit in 38 and 53% in two studies conducted in different
countries in Southeast Asia [7,16]. In Cambodia it has been
shown that fake ART was sold by 71% of local drug ven-
dors [56]. Although several studies have reported on fakeand substandard anti-malarials, just a few important stud-
ies are listed in Additional file 1.Impact on public health
Impact of counterfeit anti-malarials: preventable
Fake anti-malarials usually contain no or less active ingre-
dient so that the unwitting patient is at substantial risk of
developing severe malaria and dying [49]. Seiter [15] tried
to quantify the cost of ineffective anti-malarials from prior
estimates; he predicted that in a country of about 20 million
people, there may be four million treatments and nearly
800,000 cases treated with poor quality anti-malarials caus-
ing up to 4,000 childhood deaths, and which also contrib-
utes to the genesis of resistance because of subtherapeutic
dosage. Besides, it favours the selection and spread of resist-
ant strains [44] (Table 3), making it tougher to treat mal-
aria, even with authentic medicines. Therefore, poor-quality
anti-malarials are very likely to jeopardize the progress and
investment in control and elimination of malaria made in
the past decade [23].
Evidently, the recent emergence of artemisinin resist-
ance or tolerance of the P. falciparum strain in the
Thailand-Cambodia border [57] makes protection of ef-
fective drug supply imperative [23]. As fake anti-malarials
cannot be easily distinguished from genuine, the confi-
dence of the public healthcare providers and systems at
large is undermined [49]. Substandard and counterfeit
anti-malarials are directly or indirectly associated with
higher morbidity, mortality and stunted socio-economic
growth due to additional healthcare costs because of treat-
ment failure, and impose a severe burden of disability ad-
justed life years (DALYs) at national level [52].Factors promoting counterfeiting of anti-malarials
Need better understanding: assessing the truths and
managing the key issues
Although the counterfeit anti-malarial trade is a global
phenomenon, it is extremely difficult to assess the actual
extent worldwide, particularly in low-and middle-income
countries where malaria is a major public health issue and
there is a higher prevalence of fake drugs, mainly due to:
Table 4 Emerging opportunities to eliminate fake
antimalarials/malaria
S. No. Suggested interventions
1. Community-based anti-counterfeit campaigns
2. Determine the actual extend and nature of the problem
3. Strict law enforcement agency against all the perpetrators
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power; (c) absence or weak anti-counterfeiting laws; and,
(d) poor judicial entities, and corruption. The problem is
varied between countries and even between regions within
the same country, although industrialized countries do
have stringent regulatory mechanisms to ensure the qual-
ity of drugs.4. Setting up quality drug surveillance systems
5. Developing affordable next generation antimalarials
6. Removal of taxes and tariffs on antimalarials and other
commodities of malaria control
7. Sharing the knowledge and logistical information within and
between the endemic countries
8. Launching and maintaining the regional, national and
international databasesInadequate healthcare facilities
Many endemic countries have a free ACT treatment
policy. However, the rural poor, particularly those living in
remote areas have to walk/travel a long distance to access
free treatment. Many villages are inaccessible by road, and
only a limited number of health facilities have a regular
supply of ACT [25]. Eventually, these people will deal with
drug vendors, who knowingly or unknowingly sell fake or
substandard drugs, which has ultimately led to the emer-
gence of drug resistance and treatment-failure, and severe
morbidity and mortality.Lack of awareness: unwitting
In endemic regions anti-malarials are widely distributed
and self-prescribed (incorrectly and correctly) for many
febrile episodes attributed to malaria [23]. Fake drugs
are highly sophisticated, including convincing packaging,
holograms and marketing, and represent a major tech-
nical and law enforcement challenge [55]. In general,
poor patients and public healthcare stakeholders have
inadequate awareness on fake anti-malarials and their
potential hazards [58]. Licensed distributors, pharma-
cists, health care providers, or patients are unable to dis-
tinguish authentic medicines [21], which mean the issue
is prone to under-reporting biases. A study of the pack-
aging of the genuine and counterfeit anti-malarials sold
in Uganda [59] shows that it is extremely difficult, even
for educated personnel, to distinguish them.Emerging opportunities: looking to the future -new
science and policies
Fraud of anti-malarials is well-organized and wide-
spread in Southeast Asia and Africa; it can be con-
fronted by multilateral, global, scientific research and
multinational approaches that implement multiple, paral-
lel, anti-counterfeit strategies with a strong political com-
mitment by the regional, national and international
networks and cooperation protocols (Table 4). There-
fore, identifying and adopting existing as well as
emerging opportunities to preserve the efficiency of
one of the key arsenals, such as ACT, is paramount
in the fight against malaria, otherwise fake anti-malarials
may lead to serious, global, clinical, public health disaster
in the near future.Needs more precise prevalence: real insight required
The counterfeit industry is dominating nearly half of the
pharmaceutical industry and has become a billion-dollar
business. However, acquiring reliable estimates on the
clinical, public health and socio-economic impact is im-
precise and unclear [53]. Consequently, today’s estimates
or predictions may likely be the tip of the iceberg. Asses-
sing the actual nature, extent and cost of the counterfeit
issue will improve our understanding, and inform prior-
ities in terms of resource mobilization and allocation to
address this crisis appropriately. It may facilitate the
identification and implementation of appropriate anti‐
counterfeit strategies by bolstering the evaluation of
existing interventions and the implementation of cost‐ef-
fective practices [53].
Innovative next generation tools and simple techniques:
achievable
Counterfeiters are well funded with sophisticated equip-
ment to manufacture and supply fake anti-malarials.
Currently a number of different approaches are being
undertaken to identify fake drugs. However, lack of inex-
pensive tools is one of the major impediments for their
elimination/eradication. Recently, the US Food and Drug
Administration (FDA) [60] developed a hand-held coun-
terfeit detection device (CD-3) (Figure 3) to identify
counterfeit or substandard anti-malarials, including falsi-
fied products. CD-3 illuminates a product with a variety
of wavelengths of light to provide a visual comparison of
an unverified product with an authentic sample (Figure 3).
This allows inspectors to identify counterfeit anti-
malarials and remove them from the supply chain. Min-
imal scientific or technical background is enough to
operate the device and it can be used even in remote
communities or in places with only very basic health
care systems [60]. In fact, it is a low-cost and effective
counterfeit drug-testing tool that was already in usage
in 50 FDA field laboratories. A study is under-way to
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and it will be available in all malaria endemic settings
very soon.
Besides sample chemical profiling, researchers use fo-
rensic palynology to study pollen contamination within
fake drugs in order to detect the probable location of
manufacture enabling the fight against fake medicines
[61]. However, only a limited number of laboratories are
equipped to perform thorough forensic chemistry of fakes.
Further scientific research and development is called for
to design user-friendly, low-cost and robust portable
(hand-held) devices and techniques for drug quality
screening and assessment, and for the detecting and
identifying of marker compounds and chemical profiling
[62] to determine authenticity of anti-malarials in resource-
constrained regions of Asia and Africa in real settings.Counter-measures
Global policy on counterfeit drugs: calls for immediate
stringent measures
Initially fake antimalarials have received a very less at-
tention than the other malaria control interventions.
However, significant efforts have been made, and more
stringent measures are needed to curb this harmful prac-
tice effectively [52]. Public health institutions, ministries
and attorneys must take the lead in countering poor-
quality drugs. A balance has to be struck between the
need to make affordable anti-malarials available to
everyone and ensure the quality of drugs without com-
promise [63]. Furthermore, establishing an international
counterfeit database is imperative to obtain a strategic
and operational intelligence in the fight against fakes
[64]. Additionally, there is a need for a global anti-
counterfeit strategy to regulate and monitor pharma-
ceutical industries and drug markets, with provision at
international, national, as well as regional-base for the
regulation of all medicines, particularly anti-malarials,
including alternative and complementary medicines by
adopting local conditions and demands. These can en-
sure access to quality anti-malarials in the future.Require strict law-enforcing agency: strict with the
principles
Countries do try their best, but the counterfeiting industry
is well organised and does not even shy away from killing
government officials. For instance Dr. Dora Akunyili,
the former Director General of the National Agency for
Food and Drug Administration and Control (NAFDAC),
Nigeria had been targeted by a drug gang of counterfeit
medicine, since she had put them out of business. Finally,
she has expressed as follows ‘malaria can be prevented,
HIV/AIDS can be avoided and armed robbery may kill a
few at a time, but fake drugs kill en masse [65]’.Therefore, speedy criminal investigations and legal ac-
tions against all perpetrators, including manufacturers
and distributors [49], is imperative to dismantle or dis-
rupt the illicit trade of fake anti-malarials. Counterfeiting
of medicines is a crime against intellectual property with
civil and/or administrative penalties under specific acts,
rather than as a public health threat warranting criminal
sanctions [66]. The weakness of federal drug regulation
agencies and systems is one of the key elements favour-
ing the spread and persistence of counterfeit drugs.
Therefore, stringent pre- and post- anti-malarial drug
surveillance is vital in all malaria-endemic countries of
sub-Saharan Africa and Southeast Asia [36], with strong
law enforcement and adequate monetary support and re-
sources. Tragically, these core elements are deficient in
most malaria-endemic settings.
It has been estimated that out of the 193 WHO mem-
ber states, only about 20% are known to have well-
developed drug policies and law enforcement agencies.
Only 50% of the member states implement regulations
at various levels and 30% have no medicinal regulation
in place [67]. However, active collaboration at all levels
(regional, national and international) is a key to annihi-
late fake medicine by sharing the logistic information
and technical skills with cross-border approaches. These
key demands must be fulfilled; otherwise, fake anti-
malarials may likely to jeopardize the impressive gains
of the past decade in malaria control.
Development of affordable novel anti-malarials:
unavoidable
In past decades significant efforts have been made to de-
velop new anti-malarials to evade the emergence and
spread of resistance, by means of new bio-active mole-
cules with novel mechanisms. The persistent threat calls
for continual action [104]. Recent genome-based tech-
nologies and in vitro screening of whole parasites have
broadened the range of therapeutic targets and have ac-
celerated the development of new generation anti-
malarials [68]. MMV is committed to building a strong
pipeline of molecules leading to the next generation of
high-quality anti-malarials to attack malaria parasites
through different mechanisms [48].
Over the centuries, more than a thousand plant spe-
cies have been used as anti-malarial agents in resource-
poor settings. However, their clinical efficacy, quality,
and safety are a matter of grave concern. Plant-derived
compounds will still be an essential aspect of the thera-
peutic array of new anti-malarials [25]. As the world’s
potential anti-malarials, such as quinine and artemisinin,
have been derived from the ancient herbal remedy for
malaria, it has driven several researchers to develop and
deploy an affordable anti-malarial to attack the various
stages of malarial parasites. The cheaper anti-malarials
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covery pipeline by bringing all stakeholders, such as
traditional healers, ethnobotanists, scientists, medical
entomologists, pharmacists, universities, and research
institutions to a common platform to isolate and identify
lead compounds to develop the next generation of af-
fordable anti-malarials to combat multidrug-resistant
strains effectively [25].
Free supply of potent anti-malarials: ambition
It has been estimated that one-third and nearly half of
the anti-malarials are fake or substandard in resource-
constrained settings of sub-Saharan Africa and Southeast
Asia, respectively. It is well known that malaria is a dis-
ease of poverty and a cause of poverty [28] and the ma-
jority of victims belong to low socio-economic status
and are unable to access more expensive ACT. Conse-
quently, they procure cheaper fake anti-malarials. An ap-
propriate drug distribution policy, ideally low-priced or
free genuine drugs [52], would hamper the counterfeit in-
dustry. It is indeed a Herculean task, but one that can be
attained with the pecuniary aid of international/national
donors, malaria control partners, and non-governmental
organizations. In addition, even if anti-malarials are pro-
duced at very low cost or donated for free, it can be-
come expensive along the supply chain to the end user.
Therefore, adequate measures must be identified and
implemented to confront these barriers.
Health education campaigns and programmes
Health professionals should be self-motivated and ac-
tively involved in educating the public and patients
about counterfeiting in terms of identification, preven-
tion and the repercussions. Pharmacists, nurses and phy-
sicians, as well as pharmaceutical companies and their
distributors need to be remaining vigilant about counter-
feiting in order to best prepare for encounters with sus-
picious products [24]. All countries, interested parties
and stakeholders must act together on a common plat-
form to improve the quality and supply of several life-
saving drugs, particularly anti-malarials.
Study limitations and strengths
When considering the findings of this review, the risk of
publication bias cannot be ruled out, particularly for
positive findings relating to counterfeit anti-malarials,
where it is possible for the studies with null findings to
be under-published. It was not possible to produce an
Egger funnel plot to formally assess the risk of publica-
tion bias, for the same reasons that meta-analysis was
not performed, namely the heterogeneity in the study
designs, outcome measures, analysis strategies, and pop-
ulations in the included studies. Reporting bias within
individual studies may also be a factor, many of whichmight have explored the effects of multiple factors on
fake anti-malarials. The incomplete retrieval of identi-
fying research and the lack of published protocols for
the included studies did not allow the author to estimate
the magnitude of this potential bias. The strength of
the review is the addition of forward and backward
searching methods to the initial database search for
articles. A number of additional studies were identi-
fied using these methods, before reaching a saturation
point at which the only relevant studies identified
were included.
Conclusion
Counterfeiting of anti-malarials is an attack on global
public health. This persistent threat has torn society
by imposing severe menace in all spheres of clinical,
socio-economic, and public health. The majority of
victims often belong to underprivileged sections of
society. They primarily prefer self-medication from in-
formal, private, pharmaceutical sectors owing to the
inaccessibility and unaffordability of quality healthcare
medicines. The counterfeiters produce fake anti-malarials
and distribute in resource-poor settings. Fortunately, there
is an unprecedented awareness among all stakeholders
due to adverse repercussions of fake anti-malarials.
An urgent and intensified effort is imperative in terms
of multi-layered approaches and multi-disciplinary sci-
entific research and policies to prevent a public health
disaster.
In order to combat global counterfeiting, the findings of
this scrutiny emphasize the following stringent measures
to ensure the availability of lower-priced, genuine anti-
malarials: (a) determining the actual extent of the prob-
lem; (b) community-based, anti-counterfeit campaigns; (c)
strict law enforcement agencies against all perpetrators;
(d) setting up quality drug surveillance systems; (e) devel-
oping affordable next generation anti-malarials; (f) re-
moval of taxes and tariffs on anti-malarials and other
commodities of malaria control; (g) sharing the knowledge
and logistical information within and between the en-
demic countries; (h) launching and maintaining national
and international databases; (i) establishing adequate ana-
lytical laboratories; (j) imposition of price controls; (k)
post-market surveillance; (l) supply chain security for
active pharmaceutical ingredients and medicinal prod-
ucts; and (m) distribution of low-cost (ideally free) potent
anti-malarial through health care facilities and community
healthcare workers. These integrated and multivalent
strategies could save millions of avoidable malaria-related
illnesses and deaths, and ensure access to potent anti-
malarial tools to prevent the emergence/spread of
multidrug-resistant strains. This shall offer the oppor-
tunity to build not only counterfeit-free world, but
also the long-term goal of a malaria-free future.
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